Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label visilizumab for perianal fistulas in Crohn's disease
2004-004387-72Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Jan 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of visilizumab in Crohn's disease and anal fistula, sponsored by PDL BioPharma. Primary endpoint: Clinical response of perianal fistulas. Started Jan 2005; status: completed.
02
Drugs
visilizumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2004-004387-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004387-72.